statin utilization in primary prevention in patients with diabetes mellitus in hong kong
DESCRIPTION
Statin Utilization in Primary Prevention in Patients with Diabetes Mellitus in Hong Kong. Vivian Lee, Pharm.D. Assistant Professor School of Pharmacy The Chinese University of Hong Kong. Disease Prevalence and Risk. Prevalence & incidence of diabetes mellitus (DM) in HK - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Statin Utilization in Primary Prevention in Patients with Diabetes Mellitus in Hong Kong](https://reader036.vdocuments.mx/reader036/viewer/2022062315/568159a6550346895dc70aec/html5/thumbnails/1.jpg)
Statin Utilization in Primary Prevention in Patients with
Diabetes Mellitus in Hong Kong
Vivian Lee, Pharm.D.
Assistant Professor
School of Pharmacy
The Chinese University of Hong Kong
![Page 2: Statin Utilization in Primary Prevention in Patients with Diabetes Mellitus in Hong Kong](https://reader036.vdocuments.mx/reader036/viewer/2022062315/568159a6550346895dc70aec/html5/thumbnails/2.jpg)
Disease Prevalence and Risk
Prevalence & incidence of diabetes mellitus (DM) in HKDM pts has 2-4 fold increase risk of developing CHD & strokeDM = Coronary heart disease (CHD) risk equivalent*
10-yr risk of CHD >20%Low-density lipoprotein-cholesterol (LDL) goal for high-risk <2.6mmol/L
Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) JAMA 2001;285:2486-2497.
![Page 3: Statin Utilization in Primary Prevention in Patients with Diabetes Mellitus in Hong Kong](https://reader036.vdocuments.mx/reader036/viewer/2022062315/568159a6550346895dc70aec/html5/thumbnails/3.jpg)
Significance of this study
Use of primary prevention in diabetic patients is still suboptimal in local practice
Portion of patients attaining target LDL (<2.6mmol) is lowObserved reluctance among physicians in titrating up dosages of statins
Findings of this study are helpful in promoting rational use of statin therapy
![Page 4: Statin Utilization in Primary Prevention in Patients with Diabetes Mellitus in Hong Kong](https://reader036.vdocuments.mx/reader036/viewer/2022062315/568159a6550346895dc70aec/html5/thumbnails/4.jpg)
Objectives
Studying the role of statins in primary prevention of cardiovascular diseases in DM patients in HK
Comparing the treatment outcomes in DM patients taking statins vs no statins
Describing the resources utilization in DM patients prescribed statins
![Page 5: Statin Utilization in Primary Prevention in Patients with Diabetes Mellitus in Hong Kong](https://reader036.vdocuments.mx/reader036/viewer/2022062315/568159a6550346895dc70aec/html5/thumbnails/5.jpg)
Methods
Retrospective chart reviewStudy sites: RH & TWEH, 2 public hospitals in HKInclusion
DM, no history of CHD/strokeF/U at RH/TWEH during 2002/03With (study group) or without (control group) lipid-lowering agent (LLA)
ExclusionCHD, MI, stroke, severe HF, angina, peripheral vascular diseaseLong-term disease (e.g. cancer, severe chronic airway disease)
![Page 6: Statin Utilization in Primary Prevention in Patients with Diabetes Mellitus in Hong Kong](https://reader036.vdocuments.mx/reader036/viewer/2022062315/568159a6550346895dc70aec/html5/thumbnails/6.jpg)
DM pts F/U at RH/TWEH during 2002/03
Pts with no h/o CHD (primary prevention)
Pts with h/o CHD (secondary prevention excluded)
Review medical charts
Pts on LLA (study group)
Pts not on LLA (control group)
LLA= lipid lowering agent
![Page 7: Statin Utilization in Primary Prevention in Patients with Diabetes Mellitus in Hong Kong](https://reader036.vdocuments.mx/reader036/viewer/2022062315/568159a6550346895dc70aec/html5/thumbnails/7.jpg)
Methods
Primary outcomeCV events (MI, CHD, stroke)
Secondary outcomeAll-cause mortality
![Page 8: Statin Utilization in Primary Prevention in Patients with Diabetes Mellitus in Hong Kong](https://reader036.vdocuments.mx/reader036/viewer/2022062315/568159a6550346895dc70aec/html5/thumbnails/8.jpg)
Methods
Investigation parametersProportion of pts taking statins
Cholesterol levels
Proportion of pts attaining cholesterol goal(i.e. <2.6mmol/L)
Choices of statins & dosage
Adverse drug effects related to statins
Occurrence of primary outcomes
![Page 9: Statin Utilization in Primary Prevention in Patients with Diabetes Mellitus in Hong Kong](https://reader036.vdocuments.mx/reader036/viewer/2022062315/568159a6550346895dc70aec/html5/thumbnails/9.jpg)
Results
![Page 10: Statin Utilization in Primary Prevention in Patients with Diabetes Mellitus in Hong Kong](https://reader036.vdocuments.mx/reader036/viewer/2022062315/568159a6550346895dc70aec/html5/thumbnails/10.jpg)
Patient Recruitment
DM patients (n 1000)
Hx of CHD / stroke (n = 310) Hx of CHD / stroke (n = 681)
Excluded
Chart a/v (n = 222)Chart n/a (n = 88)
Excluded
On LLAs (n = 75) Not on LLAs (n = 147)
![Page 11: Statin Utilization in Primary Prevention in Patients with Diabetes Mellitus in Hong Kong](https://reader036.vdocuments.mx/reader036/viewer/2022062315/568159a6550346895dc70aec/html5/thumbnails/11.jpg)
Patient Demographics
Baseline features
On LLAs
(n = 75)
Not on LLAs (n = 147)
P-value
Age (years) 67.2 (±12.7) 68.0 (±16.2) <0.05
Men 35 (46%) 75 (51%) <0.05
Smoking
Never 47 (62%) 115 (78%)
Ex-smoker 14 (19%) 20 (14%) <0.05
Current 14 (19%) 12 (8%) <0.05
![Page 12: Statin Utilization in Primary Prevention in Patients with Diabetes Mellitus in Hong Kong](https://reader036.vdocuments.mx/reader036/viewer/2022062315/568159a6550346895dc70aec/html5/thumbnails/12.jpg)
Past Medical History
Diagnosis On LLAs
(n = 75)
Not on LLAs
(n = 147)
Diabetes (Type 1) 3 (4%) 7 (5%)
Hypertension 70 (93%) 132 (90%)
Dyslipidemia 26 (34.7%) 7 (4.8%)
Congestive heart failure
9 (12%) 3 (2%)
Cardiac arrhythmias 4 (5.3%) 3 (2%)
![Page 13: Statin Utilization in Primary Prevention in Patients with Diabetes Mellitus in Hong Kong](https://reader036.vdocuments.mx/reader036/viewer/2022062315/568159a6550346895dc70aec/html5/thumbnails/13.jpg)
Past Medical History
Under-diagnosis of dyslipidemia:
For patients not on LLAs:49.0% patients had LDL-C > 2.6 mmol/L
Among them, 40.3% had LDL-C > 3.4 mmol/L
Patients were deprived of lipid-lowering treatment!
![Page 14: Statin Utilization in Primary Prevention in Patients with Diabetes Mellitus in Hong Kong](https://reader036.vdocuments.mx/reader036/viewer/2022062315/568159a6550346895dc70aec/html5/thumbnails/14.jpg)
Blood Pressure Control
Blood Pressure
On LLAs
(n = 75)
Not on LLAs
(n = 147)
P-value
SBP < 130 13 (17.3%) 26 (17.7%) <0.05
Worse BP control in the LLA group
![Page 15: Statin Utilization in Primary Prevention in Patients with Diabetes Mellitus in Hong Kong](https://reader036.vdocuments.mx/reader036/viewer/2022062315/568159a6550346895dc70aec/html5/thumbnails/15.jpg)
Glycemic Control
Blood Glucose
On LLAs
(n = 75)
Not on LLAs
(n = 147)
P-value
HbA1c 7.71 (±1.45) 7.60 (±1.50) <0.05
HbA1c < 7 16 (21%) 34 (23%) <0.05
Worse glycemic control in the LLA group
![Page 16: Statin Utilization in Primary Prevention in Patients with Diabetes Mellitus in Hong Kong](https://reader036.vdocuments.mx/reader036/viewer/2022062315/568159a6550346895dc70aec/html5/thumbnails/16.jpg)
Concurrent Medications
Medications On LLAs
(n = 75)
Not on LLAs
(n = 147)
Metformin 53 (71%) 101 (69%)
Insulin 28 (37%) 40 (27%)
Antiplatelet/
anticoagulant
33 (44%) 28 (19%)
ACEI/ARB 50 (67%) 80 (54%)
Beta Blockers 16 (21%) 35 (24%)
![Page 17: Statin Utilization in Primary Prevention in Patients with Diabetes Mellitus in Hong Kong](https://reader036.vdocuments.mx/reader036/viewer/2022062315/568159a6550346895dc70aec/html5/thumbnails/17.jpg)
Use of Lipid-lowering Agents
Simvastatin , 36%
Atorvastatin ,29%
Fluvastatin , 19%
Gemfibrozil ,13%
Cholestyramine ,3%
![Page 18: Statin Utilization in Primary Prevention in Patients with Diabetes Mellitus in Hong Kong](https://reader036.vdocuments.mx/reader036/viewer/2022062315/568159a6550346895dc70aec/html5/thumbnails/18.jpg)
Use of Lipid-lowering AgentsDrug (Daily doses) No. of patients %
Atorvastatin
10 mg 17 22.67
20 mg 5 6.67
Fluvastatin
20 mg 3 4.00
40 mg 10 13.33
60 mg 1 1.33
Simvastatin
5 mg 7 9.33
10 mg 16 21.33
20 mg 4 5.33
![Page 19: Statin Utilization in Primary Prevention in Patients with Diabetes Mellitus in Hong Kong](https://reader036.vdocuments.mx/reader036/viewer/2022062315/568159a6550346895dc70aec/html5/thumbnails/19.jpg)
Use of Lipid-lowering Agents
Drug (Daily doses) No. of patients %
Gemfibrozil
600 mg 5 4.00
1200 mg 7 9.33
Cholestyramine
12 gm 2 2.67
![Page 20: Statin Utilization in Primary Prevention in Patients with Diabetes Mellitus in Hong Kong](https://reader036.vdocuments.mx/reader036/viewer/2022062315/568159a6550346895dc70aec/html5/thumbnails/20.jpg)
Dosage Titration of Lipid-lowering Agents
Majority (n = 32, 68%) were maintained on the same dose.
A very small number (n = 4, 5%) had their dosages titrated upwards.
![Page 21: Statin Utilization in Primary Prevention in Patients with Diabetes Mellitus in Hong Kong](https://reader036.vdocuments.mx/reader036/viewer/2022062315/568159a6550346895dc70aec/html5/thumbnails/21.jpg)
Laboratory Assessments of Lipid Levels
No lipid levels within the 2-year study period:
On LLAs: n = 9 (12%)
Not on LLAs: n = 49 (33%)
Inadequate Laboratory Monitoring!
![Page 22: Statin Utilization in Primary Prevention in Patients with Diabetes Mellitus in Hong Kong](https://reader036.vdocuments.mx/reader036/viewer/2022062315/568159a6550346895dc70aec/html5/thumbnails/22.jpg)
Laboratory Assessments of Lipid Levels
Lipid panel (mmol/L)
On LLAs
(n = 75)
Not on LLAs
(n = 147)
P-value
TC 5.51 4.83 <0.05
LDL-C 3.10 2.88 <0.05
HDL-C 1.21 1.37 <0.05
TG 1.48 1.21 <0.05
![Page 23: Statin Utilization in Primary Prevention in Patients with Diabetes Mellitus in Hong Kong](https://reader036.vdocuments.mx/reader036/viewer/2022062315/568159a6550346895dc70aec/html5/thumbnails/23.jpg)
Laboratory Assessments of Lipid Levels
0
1
2
3
4
5
6
TC LDL-C HDL-C TG
Lipid Panel
On LLAs
Not on LLAs
![Page 24: Statin Utilization in Primary Prevention in Patients with Diabetes Mellitus in Hong Kong](https://reader036.vdocuments.mx/reader036/viewer/2022062315/568159a6550346895dc70aec/html5/thumbnails/24.jpg)
Laboratory Assessments of Lipid Levels
Drug No. of patients No. of patients reaching LDL target
Atorvastatin 22 (29%) 6 (27%)
Fluvastatin 14 (19%) 4 (29%)
Simvastatin 27 (36%) 9 (33%)
Gemfibrozil 10 (13%) 1 (10%)
Cholestyramine 2 (3%) 1 (50%)
![Page 25: Statin Utilization in Primary Prevention in Patients with Diabetes Mellitus in Hong Kong](https://reader036.vdocuments.mx/reader036/viewer/2022062315/568159a6550346895dc70aec/html5/thumbnails/25.jpg)
Treatment Outcomes
Primary outcome On LLAs
(n = 75)
Not on LLAs
(n = 147)
P-value
Primary Outcomes
MI 7 (9.3%) 6 (4.1%)
CHD 1 (1.3%) 7 (4.8%)
Stroke 4 (5.3%) 2 (1.4%)
TOTAL 12 (15.9%) 15 (10.3%) <0.05
Secondary Outcomes
All-cause mortality 5 (6.7%) 6 (4.1%) >0.05
![Page 26: Statin Utilization in Primary Prevention in Patients with Diabetes Mellitus in Hong Kong](https://reader036.vdocuments.mx/reader036/viewer/2022062315/568159a6550346895dc70aec/html5/thumbnails/26.jpg)
Treatment Outcomes
0.00%
2.00%
4.00%
6.00%
8.00%
10.00%
Myocardial
infarction
Coronary heart
disease
Stroke All-cause
mortality
On LLAs
Not on LLAs
![Page 27: Statin Utilization in Primary Prevention in Patients with Diabetes Mellitus in Hong Kong](https://reader036.vdocuments.mx/reader036/viewer/2022062315/568159a6550346895dc70aec/html5/thumbnails/27.jpg)
Adverse Drug Reactions
Elevation in liver transaminases reported in 7 patients (9.3%)
Myopathy reported in one patient (1.3%)
Otherwise well-tolerated
![Page 28: Statin Utilization in Primary Prevention in Patients with Diabetes Mellitus in Hong Kong](https://reader036.vdocuments.mx/reader036/viewer/2022062315/568159a6550346895dc70aec/html5/thumbnails/28.jpg)
Conclusion
Diabetic population is at high risk of CV complications
Majority had unsatisfactory LDL levelsLess than 40% received primary preventionBenefits of primary prevention was not well recognized in local practice
Problems in prescribing Under-dosing of LLALack of laboratory monitoring of cholesterol levelsPatients’ non-compliance
Need to establish and promote appropriate primary prevention in diabetic population